Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
4 Tampilan
• 07/30/23
0
0
Menanamkan
administrator
Pelanggan
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru